دورية أكاديمية
Impaired immunogenicity after vaccination for SARS-CoV-2 in patients with gastrointestinal cancer: does tumor entity matter?
| العنوان: | Impaired immunogenicity after vaccination for SARS-CoV-2 in patients with gastrointestinal cancer: does tumor entity matter? |
|---|---|
| المؤلفون: | Monin MB; Department of Internal Medicine I, University Hospital Bonn, Bonn, Germany.; German Centre for Infection Research (DZIF), Partner-site Cologne-Bonn, Bonn, Germany., Gorny JG; Department of Internal Medicine I, University Hospital Bonn, Bonn, Germany., Berger M; Institute for Medical Biometry, Informatics and Epidemiology, Bonn University Hospital, Bonn, Germany., Baier LI; Department of Internal Medicine I, University Hospital Bonn, Bonn, Germany., Zhou T; Department of Internal Medicine I, University Hospital Bonn, Bonn, Germany., Mahn R; Department of Internal Medicine I, University Hospital Bonn, Bonn, Germany., Sadeghlar F; Department of Internal Medicine I, University Hospital Bonn, Bonn, Germany., Möhring C; Department of Internal Medicine I, University Hospital Bonn, Bonn, Germany., Boesecke C; Department of Internal Medicine I, University Hospital Bonn, Bonn, Germany.; German Centre for Infection Research (DZIF), Partner-site Cologne-Bonn, Bonn, Germany., van Bremen K; Department of Internal Medicine I, University Hospital Bonn, Bonn, Germany.; German Centre for Infection Research (DZIF), Partner-site Cologne-Bonn, Bonn, Germany., Rieke GJ; Department of Internal Medicine I, University Hospital Bonn, Bonn, Germany.; German Centre for Infection Research (DZIF), Partner-site Cologne-Bonn, Bonn, Germany., Schlabe S; Department of Internal Medicine I, University Hospital Bonn, Bonn, Germany.; German Centre for Infection Research (DZIF), Partner-site Cologne-Bonn, Bonn, Germany., Breitschwerdt S; Department of Internal Medicine I, University Hospital Bonn, Bonn, Germany.; German Centre for Infection Research (DZIF), Partner-site Cologne-Bonn, Bonn, Germany., Marinova M; Department of Nuclear Medicine, University Hospital Bonn, Bonn, Germany., Schmidt-Wolf IGH; Department of Integrated Oncology, Center for Integrated Oncology (CIO), University Hospital Bonn, Bonn, Germany., Strassburg CP; Department of Internal Medicine I, University Hospital Bonn, Bonn, Germany., Eis-Hübinger AM; Institute of Virology, Bonn University Hospital, Bonn, Germany., Gonzalez-Carmona MA; Department of Internal Medicine I, University Hospital Bonn, Bonn, Germany. |
| المصدر: | Journal of gastrointestinal oncology [J Gastrointest Oncol] 2023 Jun 30; Vol. 14 (3), pp. 1218-1234. Date of Electronic Publication: 2023 Jun 26. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: AME Publishing Group Country of Publication: China NLM ID: 101557751 Publication Model: Print-Electronic Cited Medium: Print ISSN: 2078-6891 (Print) Linking ISSN: 20786891 NLM ISO Abbreviation: J Gastrointest Oncol Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Publication: Hong Kong : AME Publishing Group Original Publication: Hong Kong : Pioneer Bioscience Pub. Co. |
| مستخلص: | Background: SARS-CoV-2 immunogenicity in patients with gastrointestinal cancer (GI cancer) following second and third vaccination was analyzed. Methods: A total of 125 patients under active anticancer therapy or in follow-up care were included in this prospective study. Seroprevalence of SARS-CoV-2 anti-spike and surrogate neutralization antibodies (NABs) was measured. Results: Four weeks after second vaccination, adequate titers of SARS-CoV-2 anti-spike immunoglobulin G (IgG) [≥282.0 binding antibody units (BAU)/mL] were found in 62.2% of patients under treatment versus 96.3% of patients in follow-up care (P<0.01). Sufficient titers of SARS-CoV-2 surrogate NAB (≥85.0%) were found in 32.7% of patients under treatment versus 70.6% in follow-up care (P<0.01). Titers of SARS-CoV-2 anti-spike IgG were especially low in patients with colorectal cancer (CRC). For SARS-CoV-2 surrogate NAB, patients with hepatocellular carcinoma (HCC) and with pancreaticobiliary cancer showed the lowest titers (P<0.01). SARS-CoV-2 anti-spike IgG and SARS-CoV-2 surrogate NAB were associated with a correlation coefficient of 0.93. Reaching a titer of SARS-CoV-2 anti-spike IgG ≥482.0 BAU/mL, protective levels of SARS-CoV-2 surrogate NAB (≥85.0%) could be assumed. Following booster vaccination, all patients reached effective antibody titers. Conclusions: Patients with active GI cancer showed impaired immunogenicity after second SARS-CoV-2 vaccination which was overcome by booster vaccination. Our findings were tumor-related and pronounced in patients with CRC and HCC. Waning immunity over time and antibody escape phenomena by variant of concern Omicron must be considered in these especially vulnerable patients. Competing Interests: Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://jgo.amegroups.com/article/view/10.21037/jgo-22-1065/coif). MBM received consulting fees; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events; and support for attending meetings and/or travel from Gilead, Pfizer and Virology Education. CB received grants or contracts from any entity; consulting fees; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events; and support for attending meetings and/or travel; from DZIF, Hector Foundation, DFG, NEAT ID, AbbVie, Gilead JnJ, MSD and ViiV. He participated on a Data Safety Monitoring Board or Advisory Board; and was leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid (Mavmet Study, DAIG, EACS). GJR received travel expenses and honoraria from Gilead. SS received grants or contracts from any entity; and support for attending meetings and/or travel from German Center for Infection Research, DFG, Gilead, Abbvie and Johnson&Johnson. He holds stock or stock options (MIG9 Fonds containing BionTech). MAGC has contributed to advisory boards for Roche, Eisai. BMS, MSD and AZ. The other authors have no conflicts of interest to declare. (2023 Journal of Gastrointestinal Oncology. All rights reserved.) |
| References: | Cell. 2022 Jul 7;185(14):2422-2433.e13. (PMID: 35772405) Nat Immunol. 2020 Oct;21(10):1152-1159. (PMID: 32807942) Cell. 2021 Jan 21;184(2):476-488.e11. (PMID: 33412089) J Med Virol. 2022 Jan;94(1):388-392. (PMID: 34415572) EClinicalMedicine. 2021 Aug;38:101018. (PMID: 34278286) JAMA Oncol. 2021 Aug 1;7(8):1133-1140. (PMID: 34047765) Science. 2020 Aug 21;369(6506):956-963. (PMID: 32540903) N Engl J Med. 2021 Oct 7;385(15):1393-1400. (PMID: 34525275) Clin Chem Lab Med. 2021 Sep 08;59(12):2010-2018. (PMID: 34492749) Br J Cancer. 2000 Mar;82(5):1009-12. (PMID: 10737381) Blood. 2021 Jun 10;137(23):3165-3173. (PMID: 33861303) Vaccine. 2021 Jul 22;39(32):4423-4428. (PMID: 34210573) Nat Med. 2021 Nov;27(11):2032-2040. (PMID: 34588689) Blood Adv. 2021 Aug 24;5(16):3053-3061. (PMID: 34387648) Nat Rev Gastroenterol Hepatol. 2015 Dec;12(12):681-700. (PMID: 26484443) Cancer Discov. 2021 Oct;11(10):2430-2435. (PMID: 34475136) N Engl J Med. 2021 Jun 10;384(23):2187-2201. (PMID: 33882225) Lancet. 2020 Jun 20;395(10241):1919-1926. (PMID: 32473682) Blood Adv. 2022 Jan 11;6(1):148-151. (PMID: 34614513) Clin Cancer Res. 2021 Dec 15;27(24):6815-6823. (PMID: 34583970) Cell Biosci. 2021 Nov 21;11(1):197. (PMID: 34802457) J Natl Cancer Inst. 2022 Feb 7;114(2):203-209. (PMID: 34453830) Nat Biotechnol. 2020 Sep;38(9):1073-1078. (PMID: 32704169) N Engl J Med. 2022 Mar 17;386(11):1046-1057. (PMID: 35081293) Nature. 2021 Feb;590(7847):630-634. (PMID: 33276369) Lancet Oncol. 2022 Jun;23(6):748-757. (PMID: 35617989) N Engl J Med. 2021 Feb 4;384(5):403-416. (PMID: 33378609) N Engl J Med. 2021 Dec 16;385(25):2348-2360. (PMID: 34587382) J Hepatol. 2014 Dec;61(6):1385-96. (PMID: 25135860) Gut. 2023 Jun;72(6):1227-1229. (PMID: 35882561) Nat Med. 2021 Jul;27(7):1205-1211. (PMID: 34002089) Lancet Oncol. 2021 Jun;22(6):765-778. (PMID: 33930323) J Clin Oncol. 2022 Jan 1;40(1):12-23. (PMID: 34752147) Eur J Cancer. 2021 Nov;157:124-131. (PMID: 34508994) Lancet. 2022 Mar 5;399(10328):905-907. (PMID: 35090602) N Engl J Med. 2021 Apr 8;384(14):1372-1374. (PMID: 33691060) Can J Gastroenterol. 2000 Jul-Aug;14 Suppl B:59B-62B. (PMID: 10938507) Nat Med. 2020 Aug;26(8):1218-1223. (PMID: 32581323) J Infect Dis. 2000 Feb;181(2):757-60. (PMID: 10669371) J Infect Dis. 2022 Apr 1;225(7):1141-1150. (PMID: 34888672) Nat Rev Clin Oncol. 2022 Jun;19(6):385-401. (PMID: 35277694) N Engl J Med. 2020 Dec 31;383(27):2603-2615. (PMID: 33301246) N Engl J Med. 2020 Dec 17;383(25):2439-2450. (PMID: 33053279) Microbiol Mol Biol Rev. 2016 Oct 26;80(4):989-1010. (PMID: 27784796) Cancer Cell. 2021 Aug 9;39(8):1081-1090.e2. (PMID: 34133951) |
| فهرسة مساهمة: | Keywords: SARS-CoV-2 immunogenicity; SARS-CoV-2 surrogate neutralization antibodies; Vaccination for SARS-CoV-2; gastrointestinal cancer; vaccination failure |
| تواريخ الأحداث: | Date Created: 20230712 Latest Revision: 20230718 |
| رمز التحديث: | 20240628 |
| مُعرف محوري في PubMed: | PMC10331752 |
| DOI: | 10.21037/jgo-22-1065 |
| PMID: | 37435197 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 2078-6891 |
|---|---|
| DOI: | 10.21037/jgo-22-1065 |